Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer.

Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V, Khan J, Wei JS, Agdashian D, Tyagi M, Gangalapudi V, Fioravanti S, Walker M, Anderson V, Venzon D, Figg WD, Sandhu M, Kleiner DE, Morelli MP, Floudas CS, Brar G, Steinberg SM, Korangy F, Greten TF.

Hepatology. 2018 Dec 22. doi: 10.1002/hep.30482. [Epub ahead of print]

PMID:
30578687
2.

Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.

Yu SJ, Ma C, Heinrich B, Brown ZJ, Sandhu M, Zhang Q, Fu Q, Agdashian D, Rosato U, Korangy F, Greten TF.

J Hepatol. 2018 Nov 9. pii: S0168-8278(18)32525-X. doi: 10.1016/j.jhep.2018.10.040. [Epub ahead of print]

PMID:
30414862
3.

Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy.

Brar G, Greten TF, Brown ZJ.

Therap Adv Gastroenterol. 2018 Oct 25;11:1756284818808086. doi: 10.1177/1756284818808086. eCollection 2018. Review.

4.

Development of shellfish allergy after exposure to dual immune checkpoint blockade.

Brown ZJ, Heinrich B, Greten TF.

Hepat Oncol. 2018 Feb 9;5(1):HEP02. doi: 10.2217/hep-2017-0021. eCollection 2018 Jan.

5.

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Greten TF, Lai CW, Li G, Staveley-O'Carroll KF.

Gastroenterology. 2018 Oct 1. pii: S0016-5085(18)35082-0. doi: 10.1053/j.gastro.2018.09.051. [Epub ahead of print]

PMID:
30287171
6.

miR-130a and miR-145 reprogram Gr-1+CD11b+ myeloid cells and inhibit tumor metastasis through improved host immunity.

Ishii H, Vodnala SK, Achyut BR, So JY, Hollander MC, Greten TF, Lal A, Yang L.

Nat Commun. 2018 Jul 4;9(1):2611. doi: 10.1038/s41467-018-05023-9.

7.

Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

Brown ZJ, Yu SJ, Heinrich B, Ma C, Fu Q, Sandhu M, Agdashian D, Zhang Q, Korangy F, Greten TF.

Cancer Immunol Immunother. 2018 Aug;67(8):1305-1315. doi: 10.1007/s00262-018-2190-4. Epub 2018 Jun 29.

PMID:
29959458
8.

Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis.

Ziegler PK, Bollrath J, Pallangyo CK, Matsutani T, Canli Ö, De Oliveira T, Diamanti MA, Müller N, Gamrekelashvili J, Putoczki T, Horst D, Mankan AK, Öner MG, Müller S, Müller-Höcker J, Kirchner T, Slotta-Huspenina J, Taketo MM, Reinheckel T, Dröse S, Larner AC, Wels WS, Ernst M, Greten TF, Arkan MC, Korn T, Wirth D, Greten FR.

Cell. 2018 Jun 28;174(1):88-101.e16. doi: 10.1016/j.cell.2018.05.028. Epub 2018 Jun 14.

PMID:
29909986
9.

Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research.

Brown ZJ, Heinrich B, Greten TF.

Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):536-554. doi: 10.1038/s41575-018-0033-6. Review.

PMID:
29904153
10.

Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells.

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, Agdashian D, Terabe M, Berzofsky JA, Fako V, Ritz T, Longerich T, Theriot CM, McCulloch JA, Roy S, Yuan W, Thovarai V, Sen SK, Ruchirawat M, Korangy F, Wang XW, Trinchieri G, Greten TF.

Science. 2018 May 25;360(6391). pii: eaan5931. doi: 10.1126/science.aan5931.

PMID:
29798856
11.

Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development.

Brown ZJ, Fu Q, Ma C, Kruhlak M, Zhang H, Luo J, Heinrich B, Yu SJ, Zhang Q, Wilson A, Shi ZD, Swenson R, Greten TF.

Cell Death Dis. 2018 May 23;9(6):620. doi: 10.1038/s41419-018-0687-6.

12.

Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients.

Khanna S, Graef S, Mussai F, Thomas A, Wali N, Yenidunya BG, Yuan C, Morrow B, Zhang J, Korangy F, Greten TF, Steinberg SM, Stetler-Stevenson M, Middleton G, De Santo C, Hassan R.

Clin Cancer Res. 2018 Jun 15;24(12):2859-2872. doi: 10.1158/1078-0432.CCR-17-3757. Epub 2018 Mar 30.

PMID:
29602801
13.

The ABC of adaptive immunity in liver cancer.

Greten TF.

Hepatology. 2018 Aug;68(2):777-779. doi: 10.1002/hep.29839. Epub 2018 May 14. No abstract available.

PMID:
29427558
14.

Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma.

Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, Dang H, Greten TF, Davis JL, Zhao Y, Mehta M, Levin Y, Shetty J, Tran B, Budhu A, Wang XW.

Hepatology. 2018 Jul;68(1):127-140. doi: 10.1002/hep.29778. Epub 2018 May 9.

PMID:
29315726
15.

Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop.

Block TM, Alter H, Brown N, Brownstein A, Brosgart C, Chang KM, Chen PJ, Cohen C, El-Serag H, Feld J, Gish R, Glenn J, Greten TF, Guo JT, Hoshida Y, Kowdley KV, Li W, Lok AS, McMahon B, Mehta A, Perrillo R, Rice CM, Rinaudo J, Schinazi RF, Shetty K.

Antiviral Res. 2018 Feb;150:93-100. doi: 10.1016/j.antiviral.2017.12.006. Epub 2017 Dec 14.

16.

Cellular senescence associated immune responses in liver cancer.

Greten TF, Eggert T.

Hepat Oncol. 2017 Oct;4(4):123-127. doi: 10.2217/hep-2017-0011. Epub 2017 Nov 17. Review.

17.

Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.

Brown ZJ, Heinrich B, Steinberg SM, Yu SJ, Greten TF.

J Immunother Cancer. 2017 Nov 21;5(1):93. doi: 10.1186/s40425-017-0298-2.

18.

Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.

Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA.

Gut. 2018 Feb;67(2):380-388. doi: 10.1136/gutjnl-2017-315068. Epub 2017 Nov 17. Erratum in: Gut. 2018 Mar;67(3):594.

PMID:
29150490
19.

Does CSF1R Blockade Turn into Friendly Fire?

Greten TF.

Cancer Cell. 2017 Nov 13;32(5):546-547. doi: 10.1016/j.ccell.2017.10.012.

20.

CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC.

Greten TF, Korangy F.

Gut. 2018 May;67(5):783-784. doi: 10.1136/gutjnl-2017-315091. Epub 2017 Oct 24. No abstract available.

PMID:
29066575
21.

Targets for immunotherapy of liver cancer.

Greten TF, Sangro B.

J Hepatol. 2017 Sep 18. pii: S0168-8278(17)32287-0. doi: 10.1016/j.jhep.2017.09.007. [Epub ahead of print] Review.

PMID:
28923358
22.

Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.

Ma C, Zhang Q, Greten TF.

FEBS J. 2018 Feb;285(4):752-762. doi: 10.1111/febs.14209. Epub 2017 Sep 15. Review.

PMID:
28857485
23.

Commensal bacteria (ab)use CD8+ T cells to induce insulin resistance.

Ma C, Greten TF.

Sci Immunol. 2017 Apr 21;2(10). pii: eaan1473. doi: 10.1126/sciimmunol.aan1473. Review.

PMID:
28738021
24.

Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.

Eggert T, Greten TF.

Digestion. 2017;96(1):1-4. doi: 10.1159/000464282. Epub 2017 Jun 13. Review.

25.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.

26.

Immunosuppressive cell death in cancer.

Hou J, Greten TF, Xia Q.

Nat Rev Immunol. 2017 Jun;17(6):401. doi: 10.1038/nri.2017.46. Epub 2017 May 8. No abstract available.

27.

Treating Hepatobiliary Cancer: The Immunologic Approach.

Duffy AG, Greten TF.

Dig Dis. 2017;35(4):390-396. doi: 10.1159/000456593. Epub 2017 May 3. Review.

28.

Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.

Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF.

Clin Cancer Res. 2017 Aug 15;23(16):4633-4641. doi: 10.1158/1078-0432.CCR-16-3171. Epub 2017 May 2.

29.

Systematic evaluation of immune regulation and modulation.

Stroncek DF, Butterfield LH, Cannarile MA, Dhodapkar MV, Greten TF, Grivel JC, Kaufman DR, Kong HH, Korangy F, Lee PP, Marincola F, Rutella S, Siebert JC, Trinchieri G, Seliger B.

J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017. Review.

30.

Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma.

Duffy AG, Greten TF.

Nat Rev Gastroenterol Hepatol. 2017 Mar;14(3):141-142. doi: 10.1038/nrgastro.2017.7. Epub 2017 Feb 8. No abstract available.

PMID:
28174418
31.

Tumor regulation of the tissue environment in the liver.

Eggert T, Greten TF.

Pharmacol Ther. 2017 May;173:47-57. doi: 10.1016/j.pharmthera.2017.02.005. Epub 2017 Feb 4. Review.

32.

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.

Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF.

J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2.

33.

Shall we blame CD4 T cells for everything?

Greten TF, Korangy F.

Gut. 2017 May;66(5):763-764. doi: 10.1136/gutjnl-2016-312900. Epub 2016 Nov 1. No abstract available.

PMID:
27803114
34.

The case for immune-based approaches in biliary tract carcinoma.

Duffy AG, Makarova-Rusher OV, Greten TF.

Hepatology. 2016 Nov;64(5):1785-1791. doi: 10.1002/hep.28635. Epub 2016 Jun 18. Review.

35.
36.

Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression.

Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, Heikenwalder M, Wang XW, Zender L, Greten TF.

Cancer Cell. 2016 Oct 10;30(4):533-547. doi: 10.1016/j.ccell.2016.09.003.

37.

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI.

Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150. Review.

38.

Editorial: "Invisible" MDSC in tumor-bearing individuals after antibody depletion: fact or fiction?

Ma C, Greten TF.

J Leukoc Biol. 2016 Jun;99(6):794. doi: 10.1189/jlb.5CE0116-047R. No abstract available.

PMID:
27252522
39.

Specific immunotherapy in hepatocellular cancer: A systematic review.

Baradaran Noveiry B, Hirbod-Mobarakeh A, Khalili N, Hourshad N, Greten TF, Abou-Alfa GK, Rezaei N.

J Gastroenterol Hepatol. 2017 Feb;32(2):339-351. doi: 10.1111/jgh.13449.

PMID:
27206802
40.

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF.

Int J Cancer. 2016 Oct 1;139(7):1648-57. doi: 10.1002/ijc.30199. Epub 2016 Jun 27.

41.

Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.

Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, Greten TF, McGlynn KA.

Cancer. 2016 Jun 1;122(11):1757-65. doi: 10.1002/cncr.29971. Epub 2016 Mar 21.

42.

NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.

Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, Felsher DW, McVicar DW, Weber A, Heikenwalder M, Greten TF.

Nature. 2016 Mar 10;531(7593):253-7. doi: 10.1038/nature16969. Epub 2016 Mar 2.

43.

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.

Deming DA, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Eickhoff JC, Kolesar JM, Fioravanti S, Greten TF, Compton K, Doyle AG, Wilding G, Duffy A, Liu G.

Invest New Drugs. 2016 Apr;34(2):168-75. doi: 10.1007/s10637-015-0314-7. Epub 2015 Dec 14.

44.

A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib.

Duffy AG, Ulahannan SV, Cao L, Rahma OE, Makarova-Rusher OV, Kleiner DE, Fioravanti S, Walker M, Carey S, Yu Y, Venkatesan AM, Turkbey B, Choyke P, Trepel J, Bollen KC, Steinberg SM, Figg WD, Greten TF.

United European Gastroenterol J. 2015 Oct;3(5):453-61. doi: 10.1177/2050640615583587.

45.

FoxC1: Novel Regulator of Inflammation-Induced Metastasis in Hepatocellular Carcinoma.

Aravalli RN, Greten TF.

Gastroenterology. 2015 Oct;149(4):861-3. doi: 10.1053/j.gastro.2015.08.032. Epub 2015 Aug 21. No abstract available.

PMID:
26302490
46.

Hepatic myeloid-derived suppressor cells in cancer.

Medina-Echeverz J, Eggert T, Han M, Greten TF.

Cancer Immunol Immunother. 2015 Aug;64(8):931-40. doi: 10.1007/s00262-015-1736-y. Epub 2015 Jul 2. Review.

47.

Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.

Kruger S, Boeck S, Heinemann V, Laubender RP, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Modest DP, Stintzing S, Haas M.

Acta Oncol. 2015 Jul;54(7):993-1000. doi: 10.3109/0284186X.2015.1034877. Epub 2015 Apr 30.

PMID:
25924969
48.

Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma.

Ji J, Eggert T, Budhu A, Forgues M, Takai A, Dang H, Ye Q, Lee JS, Kim JH, Greten TF, Wang XW.

Hepatology. 2015 Aug;62(2):481-95. doi: 10.1002/hep.27822. Epub 2015 Apr 28.

49.

The yin and yang of evasion and immune activation in HCC.

Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF.

J Hepatol. 2015 Jun;62(6):1420-9. doi: 10.1016/j.jhep.2015.02.038. Epub 2015 Feb 27. Review.

50.

Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.

Ulahannan SV, Rahma OE, Duffy AG, Makarova-Rusher OV, Kurtoglu M, Liewehr DJ, Steinberg SM, Greten TF.

Hepat Oncol. 2015 Jan 1;2(1):39-50.

Supplemental Content

Loading ...
Support Center